Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital anomalous coronary artery origin disorder. With advances in ultrasound, computed tomography (CT) imaging, and other technologies, an increasing number of asymptomatic patients with ALCAPA are diagnosed and treated, and the population incidence of the disease has risen to 0.021% [1]. The disease usually exists as an isolated anomaly, though it may occasionally be associated with other cardiac malformations. The mortality rate reaches 90% in newborns up to one year of age, and the rate of sudden death in adults up to 35 years of age reaches 80% to 90%. Early diagnosis and surgical treatment in children can completely correct these anatomical abnormalities at an early stage, thereby improving cardiac function and long-term prognosis [2]. This study aimed to retrospectively analyze clinical information on patients who had ALCAPA and underwent surgery at our single center, and compared the demographic and surgical variables of ALCAPA.

For ALCAPA, the embryology may be due to abnormal development and migration of angioblast buds [4]. During the neonatal period (first 8 weeks of life), the predominant clinical manifestations include heart failure and secondary mitral regurgitation, resulting from inadequate collateral circulation between the right and left coronary systems following the physiologic decline in pulmonary vascular resistance. Affected infants typically present with nonspecific symptoms including failure to thrive and tachypnea, whereas Echo demonstrates marked left ventricular dilation and severely impaired systolic function. This condition follows a rapidly progressive course, with an untreated mortality rate approaching 90% within the first year of life [5,6]. Adult survivors typically demonstrate either right coronary artery dominance or well-developed intercoronary collaterals established in early infancy. When abundant collaterals are present, the right coronary artery provides chronic retrograde perfusion to the left coronary system, while blood shunts from the left coronary artery into the pulmonary artery due to the pressure gradient, creating the characteristic “blood-stealing syndrome”, resulting in chronic myocardial ischemia, progressive mitral valve dysfunction, and elevated risk of sudden cardiac death and life-threatening arrhythmias [6].Initial clinical screening typically involves ECG and Echo, which can reliably identify ALCAPA in experienced centers. Although invasive coronary angiography remains the diagnostic gold standard, CTA and Echo provide accurate noninvasive alternatives for initial evaluation in most cases.

Surgical intervention represents the only definitive treatment for ALCAPA and should be performed promptly upon diagnosis, regardless of patient age. The surgical objective is to establish a dual-coronary arterial system. Primary techniques include coronary reimplantation and the intrapulmonary tunnel creation (Takeuchi procedure) [7,8]. Palliative coronary ligation, while historically described, carries substantial risks of chronic myocardial ischemia and accelerated coronary atherosclerosis. Coronary reimplantation is the preferred approach, achieving anatomical correction in most cases with favorable postoperative outcomes [9]. The Takeuchi procedure remains an alternative option, though it fails to restore physiological anatomy and is associated with significant long-term complications. Late complications including tunnel leakage and supravalvular pulmonary stenosis frequently occur [10]. The Del Nido cardioplegia solution serves as a cornerstone of myocardial protection, offering superior efficacy and prolonged duration of action compared to conventional formulations. Its ability to minimize perfusion frequency renders it particularly advantageous for complex pediatric cardiac surgical procedures. Moreover, the combined aortic cross-clamping and pulmonary artery occlusion strategy provides another two critical physiological advantages: (1) hemodynamic stabilization by eliminating retrograde flow into the low-pressure pulmonary circulation (2) optimization of cardioplegia delivery by preventing washout through the anomalous coronary ostium. Systematic venting protocols before pulmonary artery reperfusion are mandatory to avoid air embolism-induced myocardial injury. In high-risk patients with severe left ventricular dysfunction and mitral valve regurgitation, perioperative extracorporeal membrane pulmonary oxygenation contributes to improved survival, and the rate of ECMO use at our institution was 13.0% (3/23), which is slightly higher than the reported average rate of 8.7% [11]. Significant debate persists in the literature about the indications for concomitant mitral valvuloplasty during primary ALCAPA repair, with particular moderate regurgitation. Isomatsu et al. [12] reported that concomitant mid-upper annuloplasty in all patients with mitral regurgitation, regardless of the degree of severity (mild-severe), was effective with a re-intervention rate of 4.2%. As described by Kudumula et al. and in the European multicenter study, only patients with moderate to severe mitral regurgitation undergo concomitant mitral valvuloplasty intraoperatively, but only when combined with organic mitral valve disease, because mitral regurgitation diminishes as cardiac function recovers [13,14]. Our institutional protocol aligns with European guidelines, advocating concomitant mitral valve repair exclusively for moderate-to-severe regurgitation with demonstrable structural abnormalities (e.g., leaflet prolapse). Among 8 such cases, 5 exhibited significant improvement, including one requiring subsequent valve replacement with favorable mid-term outcomes. For mild-to-moderate regurgitation, conservative management is preferred, as most pediatric patients demonstrate remarkable ventricular recovery (improved left ventricle dimensions and ejection fractions) within one month postoperatively. While international consensus on optimal surgical timing remains undefined, our experience strongly supports early intervention upon diagnosis to mitigate progressive myocardial injury. Although our follow-up duration precludes definitive long-term assessment, extant literature reports 20-year survival rates of 86 ± 4% [15], with outcomes continuing to improve through advancing surgical techniques. Future studies should address late coronary complications including stenosis and atherosclerotic disease. The current evidence demonstrates that postoperative EF improvement in ALCAPA patients is significantly age-dependent, with infants (<1 year) showing superior recovery compared to older children and adults. This is attributed to greater myocardial plasticity and reduced fibrosis in immature hearts, allowing near-normalization of EF when surgery is performed early [16]. In contrast, delayed repair (>1 year) often results in only marginal EF gains due to irreversible ischemic damage from coronary blood stealing. A critical window appears to exist before 6 months of age, beyond which residual ventricular dysfunction becomes more prevalent. This aligns with studies showing faster left ventricular end-diastolic diameter (LVEDD) normalization in infants [16], supporting early intervention to prevent maladaptive remodeling. Long-term survival remains favorable (86 ± 4% at 20 years), but delayed correction risks persistent ventricular dysfunction and late-onset heart failure. These findings underscore ALCAPA as a time-sensitive surgical condition, where prompt anatomical restoration optimizes myocardial salvage and functional recovery [17,18]. From a pathophysiological perspective, neonates exhibit reduced surgical tolerance due to immature organ systems, prolonged operative duration, and heightened postoperative care requirements. These factors necessitate meticulous risk-benefit assessment when determining optimal surgical timing for ALCAPA repair. This study has some limitations. As this was a single-center, retrospective study, while a high risk of selection bias maybe existed in patient selection, and the number of patients included was too small to evaluate the overall ALCAPA population. Meanwhile, the interpretation of the surgical intervention and postoperative management for patients may differ between hospitals. Therefore, further multi-center study is warranted. Moreover, we evaluated ALCAPA conditions together in infants and children with possible other coexisting symptoms, which may have influenced the outcomes. Thus, further studies with larger and more specific populations is needed.

Surgical correction of ALCPA effectively restores coronary perfusion and reduces severe mitral regurgitation, though residual ventricular dilation and moderate valvular dysfunction persist in the short-term postoperative period. Compared to older children, infant ALCAPA patients demonstrate more complex recovery trajectories, characterized by significantly prolonged ventilator dependence and hospitalization duration. Nevertheless, the overall prognosis remains favorable when timely intervention is performed.